However, resistance to BRAF/MEK inhibitors is a major impediment in melanoma therapy [10], in which melanoma cells acquire resistance due to their impressive metabolic flexibility, ranging from glycolytic over glutaminolytic to lipogenic/lipolytic phenotypes that altogether, are influenced by both intrinsic oncogenic activation and extrinsic microenvironmental factors [11, 12]. This evidence concerns the gene BRAF and melanoma.